Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001

Deep News07-26

Fosun Pharma (02196) has announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the DM1001 formulation. This medication is intended for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults.

Fosun Wanbang plans to initiate Phase I clinical trials of the drug in China once conditions are met. The drug is classified as a chemical pharmaceutical.

As of June 2026, the cumulative research and development investment by the Group in this drug amounts to approximately RMB 6.95 million, inclusive of licensing fees and unaudited. According to the latest IQVIA CHPA data, sales of the same compound drug in China were approximately RMB 375 million in 2025.

This article is based on information from Sina Finance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135683425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-26 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135683425","market":"fut","top_or_hot":-1,"title":"Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001","media":"Deep News","content":"<p><b>Fosun Pharma</b> (02196) has announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the DM1001 formulation. This medication is intended for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults.<br><br>Fosun Wanbang plans to initiate Phase I clinical trials of the drug in China once conditions are met. The drug is classified as a chemical pharmaceutical.<br><br>As of June 2026, the cumulative research and development investment by the Group in this drug amounts to approximately RMB 6.95 million, inclusive of licensing fees and unaudited. According to the latest IQVIA CHPA data, sales of the same compound drug in China were approximately RMB 375 million in 2025.<br><br>This article is based on information from Sina Finance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-26 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Fosun Pharma</b> (02196) has announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the DM1001 formulation. This medication is intended for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults.<br><br>Fosun Wanbang plans to initiate Phase I clinical trials of the drug in China once conditions are met. The drug is classified as a chemical pharmaceutical.<br><br>As of June 2026, the cumulative research and development investment by the Group in this drug amounts to approximately RMB 6.95 million, inclusive of licensing fees and unaudited. According to the latest IQVIA CHPA data, sales of the same compound drug in China were approximately RMB 375 million in 2025.<br><br>This article is based on information from Sina Finance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1135683425","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135683425","pubTimestamp":1785030095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Fosun Pharma (02196) has announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration to conduct...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0239":"医药制造","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0096":"民营医院","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","02196":"复星医药","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK1191":"制药","BK1593":"医美概念股","BK0175":"白马股","BK0060":"抗癌","MDTX":"Corgi MediaTek 2x Daily ETF","PSYK":"PSYK ETF","BK1515":"抗疫概念","BK0196":"行业龙头"},"translate_title":"复星医药获得帕金森病治疗药物DM1001临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1,"IBBQ":1,"IBBJ":1,"PSYK":1,"MDTX":1,"BMED":1},"content_text":"Fosun Pharma (02196) has announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the DM1001 formulation. This medication is intended for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults.Fosun Wanbang plans to initiate Phase I clinical trials of the drug in China once conditions are met. The drug is classified as a chemical pharmaceutical.As of June 2026, the cumulative research and development investment by the Group in this drug amounts to approximately RMB 6.95 million, inclusive of licensing fees and unaudited. According to the latest IQVIA CHPA data, sales of the same compound drug in China were approximately RMB 375 million in 2025.This article is based on information from Sina Finance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135683425","isCrawlerRequest":true}